Back to Search Start Over

In vivo priming of natural killer T cells by dendritic cells pulsed with hepatoma-derived acid-eluted substances.

Authors :
Ishii, Ritsuko
Shimizu, Masumi
Nakagawa, Yohko
Shimizu, Kazuo
Tanaka, Shigeo
Takahashi, Hidemi
Source :
Cancer Immunology, Immunotherapy; May2004, Vol. 53 Issue 5, p383-390, 8p
Publication Year :
2004

Abstract

Many murine tumor cells express not only individual haplotype-matched class I MHC molecules, but also species-specific CD1d molecules. The former class I MHC molecules generally present internally synthesized tumor-derived peptide antigens to highly specific CD8<superscript>+</superscript> cytotoxic T lymphocytes (CTLs) in acquired immunity. In contrast, the latter CD1d molecules may present tumor-associated glycolipid antigens to broadly crossreactive natural killer T (NKT) cells, which might correlate with controlling tumor metastasis. Here, we showed that murine hepatoma cell line Hepa1-6-derived acid-eluted substances might contain both D<superscript>b</superscript> class I MHC-restricted antigens and CD1d-restriced substances, which could sensitize not only syngeneic bone marrow-derived DCs (BM-DCs), but also allogeneic BM-DCs expressing haplotype-mismatched class I MHC and species-specific CD1d molecules. To our surprise, intravenous (i.v.) immunization of C57BL/6 mice with the former syngeneic BM-DCs carrying acid-eluted materials primed both CD4<superscript>–</superscript>CD8<superscript>–</superscript> and CD8<superscript>+</superscript> NKT cells in the spleen, whereas immunization with the latter allogeneic BM-DCs loaded the tumor-derived substances primed CD4<superscript>-</superscript>CD8<superscript>-</superscript>, but not CD8<superscript>+</superscript> NKT cells. The findings shown in the present study will open a new area for cancer immunotherapy using allogeneic DCs and tumor-derived acid-eluted substances. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
03407004
Volume :
53
Issue :
5
Database :
Complementary Index
Journal :
Cancer Immunology, Immunotherapy
Publication Type :
Academic Journal
Accession number :
15682003
Full Text :
https://doi.org/10.1007/s00262-003-0453-0